Click (NASDAQ:CLIK) Shares Down 17.4% – Time to Sell?

by · The Markets Daily

Click Holdings Limited (NASDAQ:CLIK – Get Free Report)’s share price was down 17.4% during mid-day trading on Tuesday . The company traded as low as $1.51 and last traded at $1.52. Approximately 866,407 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 2,662,997 shares. The stock had previously closed at $1.84.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Click presently has an average rating of “Sell”.

Read Our Latest Stock Report on Click

Click Trading Up 0.6%

The stock has a fifty day simple moving average of $2.13 and a 200-day simple moving average of $3.62.

Click (NASDAQ:CLIK – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $3.79 million for the quarter.

Institutional Trading of Click

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click as of its most recent filing with the Securities and Exchange Commission.

About Click

(Get Free Report)

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.

See Also